Seer, Inc. (SEER): Breakthrough Technology, Broken Commercialization, and a Live Acquisition Proposal

There are not many companies in the life sciences tools market where the technology is genuinely world-class, the scientific community is actively adopting the platform, and the stock has still fallen more than 96% from its IPO price.

Seer, Inc. (NASDAQ: SEER) is one of them. And as of April 13, 2026, its largest activist shareholder has submitted a formal non-binding proposal to acquire the company outright.

The company's Proteograph platform represents a meaningful advance in how deep proteomics gets done. The IP held up against a direct challenge from one of the largest instrument companies in the world. Population-scale studies are selecting Proteograph alongside platforms from Thermo Fisher. Third-party publications are accelerating. And the business is trading at a market cap below its cash on hand, meaning the market is assigning negative value to the operating business entirely.

This article covers what Seer actually does, why the technology matters, what has gone wrong operationally, and how the situation has now escalated from activist pressure to a formal acquisition proposal with a board response deadline of April 22, 2026.

What Seer Does

Seer was founded in 2017 in Redwood City, California by Omid Farokhzad, Philip Ma, and Robert Langer. The company's core product is the Proteograph Product Suite: an integrated proteomics platform that uses proprietary engineered nanoparticles to enrich proteins from biological samples like blood plasma before analysis on a mass spectrometer.

The underlying science is based on a phenomenon called the "protein corona." When engineered nanoparticles are introduced into a complex biological sample, proteins from the sample adsorb onto the nanoparticle surface, forming a corona layer. Different nanoparticle formulations attract different protein populations, including low-abundance proteins that are normally invisible because they are overwhelmed by highly abundant species like albumin, which alone accounts for up to 60% of total plasma protein mass.

By running a sample across multiple nanoparticle types in parallel, Proteograph creates a compressed, enriched representation of the full proteome that can be analyzed by downstream mass spectrometry. The result is deep, unbiased proteomics at a throughput and simplicity level that traditional sample preparation workflows cannot match.

The platform currently includes the Proteograph XT automation instrument, a suite of consumables including the nanoparticle reagents, the Proteograph ONE third-generation assay for population-scale studies, Proteograph DIRECT for bottom-up LC-MS analysis, and the Proteograph Analysis Suite, a cloud-based data analytics platform for quality control and interpretation.

As of full year 2025, Seer had 82 instruments installed at research institutions and pharmaceutical companies globally, up 67% year over year.

Why the Technology Matters

To understand what is at stake with Seer, it helps to understand where Proteograph sits in the proteomics workflow relative to the dominant commercial platforms.

Affinity-based platforms like Olink (now part of Thermo Fisher after its $3.1 billion acquisition in 2024) measure proteins by using antibody pairs that generate a signal only when both bind the same target protein. They are highly sensitive, highly multiplexed (Olink's Explore HT platform measures approximately 5,400 proteins), and well-suited for clinical and population-scale applications because the workflow is standardized and relatively simple. The limitation is that they only measure proteins for which antibody panels have been pre-designed, and they can be susceptible to artifacts when antibody binding is influenced by protein modifications or interactions.

Mass spectrometry-based proteomics, by contrast, measures proteins directly by their physical characteristics (mass and charge) without requiring pre-designed antibody reagents. It is comprehensive and unbiased but traditionally requires complex sample preparation and significant operator expertise. Proteograph's nanoparticle enrichment step is designed to solve the throughput and complexity problem that has historically limited mass spectrometry proteomics to small studies.

The clinical relevance was demonstrated directly in a December 2025 Nature Genetics study that used Seer's Proteograph platform in a large-scale genome-wide association study, showing that peptide-level mass spectrometry can distinguish true protein changes from potential binding artifacts in affinity-based approaches. In other words, Proteograph is not just a complement to Olink: it serves as a validation layer that catches the artifacts affinity platforms can generate.

The most recent commercial evidence of this positioning came in April 2026, when Seer announced that its Proteograph Product Suite was selected as the mass spectrometry-based proteomics workflow for PRECISE-SG100K, a landmark 100,000-person multi-ancestry population cohort in Singapore. The same 10,000-sample subset will be profiled with both Proteograph and Thermo Fisher's Olink Reveal on Orbitrap Astral instruments, explicitly positioning the two platforms as complementary tools for population-scale proteomics.

That is a significant signal. Population-scale studies selecting both Olink and Proteograph on the same samples is exactly the validation story that makes Seer's platform strategically attractive to a potential acquirer who already owns Olink.

What Has Gone Wrong

The scientific narrative is compelling. The commercial narrative is not.

Seer went public in December 2020 at a time when life sciences tool companies were receiving peak valuations. The IPO raised significant capital and gave the company the runway to build out its commercial infrastructure. Five years later, the financials tell a story of scientific progress and commercial stagnation.

Full year 2025 revenue was $16.6 million, up approximately 17% from $14.2 million in 2024. That sounds like progress until you look at the starting point: since 2022, annual revenue has increased by approximately $1.1 million in total while cash burned in operations has exceeded $160 million. The company's own CEO, in a strategic plan disclosed in October 2025, projected that Seer would not achieve profitability until 2031. The 2026 guidance midpoint implies 3% growth, or roughly $500,000 of incremental revenue.

The math is stark. To reach GAAP breakeven on its current cost structure and gross margin profile, Seer would need to grow revenue by more than 1,050%.

Gross margin improved to approximately 51% in 2025, which reflects the consumables revenue mix improving as the installed base grows. But operating expenses of $86.5 million against $16.6 million in revenue means the operating leverage story is still years away at any plausible growth rate.

The installed base numbers are the most charitable part of the story: 82 instruments representing 67% year-over-year growth is real commercial momentum. But at $16.6 million in annual revenue spread across 82 installed instruments, the revenue per instrument is modest, which suggests utilization, consumables pull-through, or both are below what the platform is capable of generating.

Seer's CEO, Dr. Omid Farokhzad, has consistently described growing confidence in the platform's value proposition and overwhelmingly positive customer feedback on earnings calls and at investor conferences. Reported total compensation for Farokhzad from 2021 through 2024 was $24.9 million, a figure now front and center in the activist's public communications.

The Activist Campaign

The governance situation at Seer has escalated rapidly in 2026, moving from open letters to a formal acquisition proposal in less than two months.

February 20, 2026: Bradley L. Radoff and Michael Torok, together with affiliated entities, filed a Schedule 13D disclosing an activist stake of approximately 6.5% of Seer's outstanding shares. The filing stated they had purchased shares because they believed the stock was undervalued and were engaging with the board on ways to enhance stockholder value, including a potential strategic review, board composition changes, and a possible sale of the company in whole or in parts.

February 23, 2026: The Radoff-JEC Group issued a public open letter to Seer's full board, detailing the case for immediate change. The letter cited the 96%+ share price decline since the 2020 IPO, the anemic revenue growth against enormous cash consumption, and the CEO's 2031 profitability target. The letter concluded that Seer cannot and should not remain a publicly traded company unless significant governance and operational changes are implemented immediately, and called for the board to commence a sale process.

February 26, 2026: On the same day it reported full year 2025 earnings, Seer's board unanimously adopted a limited-duration tax benefit preservation plan (commonly called a poison pill) structured around the company's approximately $262 million in net operating loss carryforwards. The plan prevents any stockholder from accumulating more than 4.9% of Seer's Class A stock without board approval. A stockholder filed a lawsuit in the Delaware Court of Chancery alleging that the board breached its fiduciary duties in adopting the poison pill.

March 4, 2026: The Radoff-JEC Group, by then holding approximately 7.6% of outstanding shares, sent a second letter addressed directly to the two directors identified as unconflicted independents (Meeta Gulyani and Nicolas Roelofs), explicitly bypassing the CEO-aligned majority. The letter raised concerns about the board's continued deference to Farokhzad and called on the independent directors specifically to act.

March 12, 2026: The Radoff-JEC Group met with two board members. In that meeting the board requested specific suggestions for actions to reverse the share price decline. The activist group provided suggestions including a large tender offer to retire stock, an immediate and significant operating cost reduction, separation of the Chair and CEO roles, and revoking equity grants made to Farokhzad and CFO David Horn at share prices below net cash per share. The board promised immediate feedback and engagement. It did not respond.

March 13, 2026: The board amended the poison pill to moot the pending Delaware Court of Chancery challenge without resolving the underlying governance dispute.

April 13, 2026: The Radoff-JEC Group submitted a formal non-binding proposal to acquire 100% of Seer's equity. The proposal offers $2.25 per share in cash, a 33% premium to the April 10 closing price of $1.69, plus a contingent value right (CVR) giving stockholders 80% of net proceeds from any future license, sale, or other disposition of Seer's assets, including its subsidiary PrognomiQ. The proposal is not subject to any financing conditions and requires at least $215 million of net cash at closing. Baker Botts and Olshan Frome Wolosky are acting as legal advisors. The group stated it is prepared to complete due diligence and negotiate a definitive merger agreement by April 30, 2026.

Simultaneously, the Radoff-JEC Group nominated three independent director candidates for election at the 2026 annual meeting: Howard H. Berman, Joshua S. Horowitz, and Luis E. Rinaldini.

The proposal letter also disclosed additional context on CEO Farokhzad's track record across prior companies: Bind Therapeutics (filed for Chapter 11 bankruptcy protection), Selecta Biosciences (share price declined 95% between its IPO and its merger with Cartesian Therapeutics), and Senti Biosciences (share price currently down 99% since its IPO in 2021). The activists made the pointed observation that no board member has purchased Seer shares despite the stock trading at a material discount to net cash per share for over two years.

The board response deadline is April 22, 2026. After that date, the offer expires. The board has not yet publicly responded as of the date of this article.

The Patent Ruling

Running parallel to the activist campaign was a significant IP development.

Bruker Corporation, through its proteomics subsidiaries PreOmics GmbH and Biognosys AG, filed an inter partes review at the U.S. Patent and Trademark Office challenging 11 of 29 claims of Seer's core nanoparticle patent (U.S. Patent No. 11,435,360), which covers the protein corona technology underlying the Proteograph platform. The patent is owned by Brigham and Women's Hospital and exclusively licensed to Seer.

On March 23, 2026, the Patent Trial and Appeal Board issued its Final Written Decision, upholding 23 of the 29 patent claims, including five of the challenged claims and all 18 unchallenged claims. Some challenged claims were found unpatentable, but the core technology protection for Proteograph's nanoparticle protein enrichment methods remains intact.

The strategic reading of this ruling is important. Bruker is not a random challenger. Through its acquisition of Biognosys, Bruker has become one of the largest players in mass spectrometry-based proteomics services. Bruker's timsTOF instruments compete directly with the Thermo Fisher Orbitrap platforms that are typically paired with Proteograph. A successful patent challenge would have cleared the IP runway for Bruker to develop competing nanoparticle-based sample preparation technology. The Final Written Decision substantially preserves Seer's ability to defend its core IP against that competitive threat.

Either side may appeal by May 25, 2026. If Bruker appeals, the IP uncertainty persists through federal court proceedings. If neither side appeals, the ruling becomes final and significantly clarifies the competitive IP landscape.

The M&A Thesis

The activist case and the strategic logic point in the same direction: Seer is worth more as an acquisition than as a standalone public company.

The strategic acquirer universe is identifiable and motivated. Thermo Fisher acquired Olink for $3.1 billion in 2024 specifically to build out its proteomics workflow. Proteograph is scientifically positioned as the complementary tool to Olink: the PRECISE-SG100K study running both platforms on the same samples makes the combination logic explicit. An acquirer that owns both platforms would offer the most comprehensive sample-to-insight proteomics workflow available commercially.

The valuation arithmetic is striking. With approximately $240 million in cash and investments on the balance sheet and a market cap of roughly $110 million, Seer is trading at approximately 55 cents on the dollar of cash alone. An acquirer paying a 50% premium to the current stock price would acquire the cash, the IP portfolio (240 patents and pending applications, 80 issued), the installed base of 82 instruments generating recurring consumables revenue, the population-scale study relationships, and the scientific credibility, for a net cost below zero after the cash is netted out.

The risk an acquirer needs to price: the commercial infrastructure has not demonstrated the ability to drive meaningful revenue growth. Any acquirer is effectively buying the IP and the scientific platform, not a working commercial engine. The revenue needs to be rebuilt inside a larger organization with better distribution and a larger installed customer base to cross-sell into.

That is a risk profile that is well-suited to a large strategic acquirer (who already has the distribution and customer relationships) and less well-suited to a financial buyer (who would need to build the go-to-market from scratch).

What Happens Next

This situation is no longer hypothetical. There is a live acquisition proposal on the table with a hard deadline.

April 22, 2026: board response deadline. The Radoff-JEC Group has given the board until 5:00pm ET on April 22 to respond to its $2.25 per share proposal. If the board does not respond, the offer expires. A non-response is itself a decision, and it is likely to intensify the proxy fight heading into the annual meeting.

The board's options are limited. It can engage with the Radoff-JEC proposal, reject it publicly, or announce a broader strategic review to run a competitive process. Any of the three paths creates pressure. Engagement legitimizes the activist thesis. Rejection with no alternative invites a proxy fight. A strategic review with no financing condition and a 33% premium already on the table sets a floor that any competing bidder would need to clear.

The CVR structure is worth noting. The $2.25 cash price is calculated to approximately cover the cash on the balance sheet (the proposal requires at least $215M net cash at closing). The CVR, which gives stockholders 80% of net proceeds from any subsequent asset monetization, is where the activists believe the real technology value lives. PrognomiQ, a subsidiary mentioned specifically in the proposal letter, is a multi-omics diagnostics platform spun out of Seer's technology. Any strategic acquirer for the combined assets would represent upside above the $2.25 floor.

The proxy fight is now formally underway. The director nominees filed alongside the acquisition proposal (Berman, Horowitz, Rinaldini) give the Radoff-JEC Group a mechanism to change board composition even if the acquisition proposal is rejected. A successful proxy campaign that seats even two of the three nominees would shift the governance dynamic inside the boardroom materially.

The patent appeal window closes May 25, 2026. If Bruker does not appeal the PTAB ruling, the IP clarity around Proteograph's core nanoparticle technology becomes final. That matters for any acquirer's diligence.

Q1 2026 earnings are expected around May 12, 2026. The next financial data point will either strengthen or weaken the case that commercial momentum is improving. Given the 2026 guidance midpoint implies only 3% revenue growth, the earnings call is unlikely to change the strategic calculus significantly.

The most likely near-term scenarios in order of probability: the board announces a strategic review (acknowledging the proposal creates pressure without accepting its terms), the board rejects the proposal and the proxy fight intensifies, or a larger strategic acquirer emerges and the Radoff-JEC proposal serves as a floor in a competitive process. An outright acceptance of the $2.25 offer is the least likely scenario given the board's posture to date, but it cannot be ruled out if the independent directors conclude the alternative is a prolonged and destructive governance battle.

The MaTrx View

Seer sits at the intersection of three themes we track closely in the life sciences tools market: the consolidation of the proteomics platform layer, the governance pressures building at underfunded public biotechs, and the disconnect between scientific platform value and public market valuation that creates M&A opportunity.

What makes this situation particularly instructive is how cleanly it illustrates the problem a genuinely good technology platform can create when it is housed in a public company with a cost structure that the revenue base cannot support. The Radoff-JEC proposal is not a hostile takeover of a healthy business. It is a liquidation proposal for a business whose intrinsic asset value (cash plus IP plus scientific platform) exceeds its current enterprise value by a significant margin, and where the current management team has demonstrated no credible path to closing that gap organically.

The CVR structure in the proposal is the most interesting element from a life sciences M&A perspective. It reflects the activists' view that the $2.25 cash price covers the balance sheet but leaves the technology value as an open question. If a strategic acquirer (the most natural being a large proteomics platform company that already operates in this workflow) were to acquire Seer's assets through this structure, stockholders would participate in 80% of the value realized. That is an unusual alignment mechanism and one that reflects genuine uncertainty about what Proteograph and PrognomiQ are worth in the hands of the right owner.

The board's decision in the next 72 hours will define the next 12 months. If it engages, the M&A process begins. If it rejects and fights, the proxy contest intensifies. Either way, the status quo is no longer available.

This is Part II of our Omics Series. Part I covered the proteomics market landscape and the broader strategic context for life sciences tools M&A. Part III will cover the genomics and sequencing market.

MaTrx is an AI-native investment bank and advisory firm serving the lower middle market. We advise life sciences, proteomics, and laboratory businesses on M&A, capital raising, and restructuring.